All In Biotech

Drug Trial Radar · NCT06796907

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 305 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

305

Planned (sponsor's estimate)

Start

Mar 4, 2025

Primary completion

Jun 21, 2027

Study completion Oct 10, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable Mocertatug Rezetecan (Mo-Rez) is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.

Conditions

  • Tumours, Gynecological

Interventions

  • Mo-RezDrug

    Mo-Rez will be administered intravenously (IV).

  • DostarlimabDrug

    Dostarlimab will be administered IV.

  • BevacizumabDrug

    Bevacizumab will be administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of participants with dose limiting toxicities (DLTs)Time frame: Approximately 7 months
  2. Part A: Number of participants with adverse events (AEs), immune-mediated adverse events (imAEs), adverse events of special interest (AESI), serious adverse events (SAEs) by SeverityTime frame: Up to approximately 22 months
  3. Part A: Number of participants with adverse events (AEs), immune-mediated adverse events (imAEs), adverse events of special interest (AESI), serious adverse events (SAEs) by FrequencyTime frame: Up to approximately 22 months
  4. Part B: Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 37 months

Locations

83 sites in 23 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    La Jolla, California · Recruiting

  • GSK Investigational Site

    Aurora, Colorado · Recruiting

  • GSK Investigational Site

    Rochester, New York · Recruiting

  • GSK Investigational Site

    Durham, North Carolina · Recruiting

  • GSK Investigational Site

    Columbus, Ohio · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    CABA, Argentina · Recruiting

  • GSK Investigational Site

    Viedma, Argentina · Recruiting

  • GSK Investigational Site

    Liverpool, New South Wales, Australia · Recruiting

  • GSK Investigational Site

    Wollongong, New South Wales, Australia · Recruiting

  • GSK Investigational Site

    Brussels, Belgium · Recruiting

  • GSK Investigational Site

    Ghent, Belgium · Recruiting

  • GSK Investigational Site

    Leuven, Belgium · Recruiting

  • GSK Investigational Site

    Liège, Belgium · Recruiting

  • GSK Investigational Site

    Barretos, Brazil · Recruiting

  • GSK Investigational Site

    Goiânia, Brazil · Recruiting

  • GSK Investigational Site

    Natal, Brazil · Recruiting

  • GSK Investigational Site

    Porto Alegre, Brazil · Recruiting

  • GSK Investigational Site

    São Paulo, Brazil · Recruiting

  • GSK Investigational Site

    Vitória, Brazil · Recruiting

  • GSK Investigational Site

    Vancouver, British Columbia, Canada · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Herlev, Denmark · Recruiting

  • GSK Investigational Site

    København Ø, Capital Region, Denmark · Recruiting

  • GSK Investigational Site

    Helsinki, Finland · Recruiting

  • GSK Investigational Site

    Tampere, Finland · Recruiting

  • GSK Investigational Site

    Lyon, France · Recruiting

  • GSK Investigational Site

    Marseille, France · Recruiting

  • GSK Investigational Site

    Montpellier, France · Recruiting

  • GSK Investigational Site

    Pierre-Bénite, France · Recruiting

  • GSK Investigational Site

    Villejuif, France · Recruiting

  • GSK Investigational Site

    Cologne, Germany · Recruiting

  • GSK Investigational Site

    Leipzig, Germany · Recruiting

  • GSK Investigational Site

    München, Bavaria, Germany · Recruiting

  • GSK Investigational Site

    Mainz, Rhineland-Palatinate, Germany · Recruiting

  • GSK Investigational Site

    Athens, Greece · Recruiting

  • GSK Investigational Site

    Athens, Greece · Recruiting

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.